Caitlin McClain, a nurse and Clostridioides difficile infection (CDI) survivor, says pharmacists are well placed to help patients tell routine antibiotic adverse effects apart from CDI, which could lead to earlier diagnosis.
|Articles|August 27, 2021
Pharmacy Clinical Pearl of the Day: Immune Globulins
Author(s)Saro Arakelians, PharmD
Immune Globulins are injections that are used to treat immunodeficiency disorders.
Advertisement
Clinical Pearl of the Day: Immune Globulins
Immune globulins are injections that are used to treat immunodeficiency disorders.
Explanation:
- Part of immunizing agents
- Made up of antibodies
- Given intravenously and subcutaneously
- Used when the body does not make enough antibodies
- The antibodies from IVIG usually last for weeks to months
- Can be given for diseases such as immune thrombocytopenia, Guillain-Barre Syndrome, and chronic inflammatory demyelinating polyneuropathy (CIDP)
- Examples: Gamunex, Privigen, Octagam, Gammagard, Hyqvia, Hizentra, Cuvitru
Reference:
Advertisement
Related to this article
A disease-modifying therapy for stage 3 T1D, a second once-weekly insulin, and automated insulin delivery for T2D mark a busy year in diabetes care.
October’s pain management coverage examined postoperative suzetrigine, pharmacist follow-up for cancer-related neuropathic pain, constipation prevention, and counseling patients concerned about prescribed opioids.
CDC surveillance data show that approximately 10% of adults hospitalized with RSV died during hospitalization or within 60 days of discharge.
From AKI dosing to CKM therapeutic inertia, experts at ASN Kidney Week 2026 pointed to pharmacists as key to moving new kidney data into practice.
Jai Radhakrishnan, MD, MBBS, MS, FASN, discusses why IgG4-related kidney disease is often missed and what the MITIGATE subgroup data presented at ASN Kidney Week 2026 show.
Before lung cancer therapy begins, diagnostic findings and treatment readiness shape care, creating opportunities for pharmacists to help patients start safely.
VAX-31 met all primary immunogenicity end points against PCV20 and PCV21 in the pivotal OPUS-1 trial.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Diabetes Awareness Month Opens Amid New T1D, T2D Approvals
2
October 2026 in Pain Management: 4 Updates on Treatment and Pharmacy Practice
3
What Happens Before the First Dose? 5 Steps That Shape Lung Cancer Treatment
4
COVID-19 ‘Is Not Done With Us’: Pharmacist Urges Continued Vaccination Ahead of Seasonal Peaks
5